Skip to content

Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI)

Development of Deep Learning Models for Detection of Neurodegenerative Diseases Using Speech - a Danish Language-based Artificial Intelligence Study (DetectAI)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07200739
Acronym
DetectAI
Enrollment
440
Registered
2025-10-01
Start date
2026-06-01
Completion date
2028-07-01
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia (Diagnosis), Alzheimer Dementia (AD), Vascular Dementia (VaD), Lewy Body Dementia (LBD), Frontotemporal Dementia (FTD), Mild Cognitive Impairment (MCI), Depression - Major Depressive Disorder, Stress, Cognitive Impairment

Keywords

artificial intelligence, speech-based artificial intelligence, artificial intelligence in dementia diagnostics, artificial intelligence for dementia screening, artificial intelligence for dementia classification, speech based artificial intelligence, dementia, Vascular dementia (VaD), Alzheimer dementia (AD), Lewy Body Dementia (LBD), Frontotemporal Dementia (FTD), Mild Cognitive Impairment (MCI), Depression - Major Depressive disorder, Dementia (diagnosis), machine learning, stress, Cognitive Impairment, deep learning

Brief summary

The goal of this observational study is to learn if an artificial intelligence (AI)-based speech analysis tool can identify which patients with memory problems need specialist evaluation at a memory clinic. The main questions it aims to answer are: Can the AI model accurately distinguish between patients who need referral to a memory clinic (those with dementia or Mild Cognitive Impairment) and patients who don't (those with normal cognition or memory problems from other causes like depression)? Which speech patterns and cognitive test features are most useful for making this distinction? Researchers will compare speech recordings and cognitive test results from patients diagnosed with dementia or MCI to those from patients with normal cognition or non-neurodegenerative cognitive impairment to see if the AI model can reliably predict who needs specialist dementia care. Participants will: Complete standard cognitive tests at the memory clinic Perform structured speech tasks while being audio-recorded Receive their usual clinical evaluation and diagnosis from memory clinic specialists The results of this study will help develop a tool that can assist doctors in making faster, more accurate decisions about which patients need specialist dementia evaluation, potentially leading to earlier diagnosis and better patient outcomes.

Detailed description

Background Dementia is a growing public health challenge, and early and accurate diagnosis is essential for effective care and potential future disease-modifying treatments. Current diagnostic pathways are resource-intensive and associated with long waiting times. Speech reflects cognitive functioning, and recent international studies have shown that machine learning models can detect dementia-related patterns in speech recordings with promising accuracy. This study aims to develop a speech-based deep learning model in a Danish setting, providing a non-invasive and scalable screening tool for use in primary care. Study Design and Sampling Methods This is an observational, cross-sectional study. Participants are recruited using two different sampling strategies corresponding to two artificial intelligence (AI) model development tracks: Track A (Model A) - Retrospective case-control sampling: This track addresses a focused diagnostic task: identification of Mild Cognitive Impairment (MCI). Participants are patients with a recent diagnosis from the memory clinic at Region Zealand University Hospital (ZUH). Sampling uses convenience sampling prioritizing patients who live close to the hospital, as data collection occurs during home visits. Patients with more recent diagnoses are prioritized to minimize the risk that participants have progressed to a new disease stage since diagnosis (e.g., from MCI to dementia). Track B (Model B) - Prospective consecutive sampling: This track uses prospective inclusion of newly referred patients to the memory clinic without pre-selection by diagnosis, reflecting a real-world clinical screening population. All eligible, consenting patients are included consecutively at their first clinic visit, before final diagnosis is established. Model Development Following Best Practice Guidelines The study follows TRIPOD-AI (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis - Artificial Intelligence) and PROBAST-AI (Prediction model Risk Of Bias ASsessment Tool - Artificial Intelligence) guidelines for developing and validating clinical prediction models. Key methodological features include: Transparent model development: All preprocessing steps, feature extraction methods, model architectures, and hyperparameters will be documented Robust validation strategy: Data will be split into training, validation, and hold-out test sets for in-depth internal validation. Minimizing bias: Participant selection, predictor measurement, outcome determination, and statistical analysis are designed to minimize bias according to PROBAST-AI domains Clinically relevant performance metrics: Sensitivity, specificity, area under the receiver operating characteristic curve (AUC-ROC), positive and negative predictive values, and calibration Interpretability: Feature importance analysis to understand which speech characteristics contribute to predictions Data Collection Speech data is collected through structured tasks including picture description, verbal fluency tests, story recall, and spontaneous speech. Audio is recorded using standardized equipment with quality control checks. Clinical diagnoses are established by experienced clinicians at the memory clinic following international diagnostic criteria.

Interventions

Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.

Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.

OTHERSpeech Task - Picture Description

Participants will be asked to describe the Cookie Theft Picture from the Boston Diagnostic Aphasia Examination. The task will take 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns.

OTHERSpeech Task - Picture Recall

Participants will be asked to recall the picture shown in the previous speech task "Picture Narrative". This task will take 2 minutes. Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.

DIAGNOSTIC_TESTMRI

For healthy controls an MRI will be conducted to provide comparable imaging and as part of screening to ensure they do not meet exclusion criteria (neuroradiological findings that could affect cognitive functions). For patient participants, imaging will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal.

DIAGNOSTIC_TESTblood sampling

Healthy control participants will undergo a standard blood test panel commonly used in dementia diagnostics. The panel includes complete blood counts, inflammatory markers, kidney- and liver function markers, thyroid-stimulating hormone (TSH), vitamine B12 and folate. These tests are performed to exclude underlying medical conditions that could mimic cognitive impairment. For patient participants, blood sampling will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal.

DIAGNOSTIC_TESTDepression screening

Performed on healthy controls to rule out depression using either the geriatric depression scale (GDS) for patients \> 65 year of age or the Major Depression Index (MDI) for patiens \<65 year of age. For patient participants, depression screening will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal.

OTHERSomatic- and neurological examination

Healthy controls will undergo a standard somatic and neurological examination to exclude conditions that may affect cognition. This includes basic neurological assessment and clinical evaluation of general health status. For patient participants, a somatic and neurological examination will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal

OTHERSpeech Task - Picture Narrative

The participant is asked to tell a brief story based on a culturally neutral picture. This task will take approximately 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns

Sponsors

Zealand University Hospital
Lead SponsorOTHER
DemensAI ApS (private tech partner, Denmark)
CollaboratorUNKNOWN

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Model A (patient participants) * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling * A diagnosis of either MCI or AD, given at the SUH memory clinic within 6 months before enrollment Model A (cognitively healthy controls) * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling Model B: * Age \> 50 years * Fluent in Danish * Minimum of 7 years of schooling

Exclusion criteria

Model A: Patients: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE score \< 16 * Concomitant diagnoses which are expected to influence cognitive impairment (eg. depression) * Patients unable to give consent * Patients with alcohol consumption \>21 standard alcohol units per week * Any history of speech or language impairment predating the current condition Cognitively healthy controls: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE \< 26 and ACE \< 90 * Clinical, laboratory, or neuroradiological findings that could affect cognitive functions * Known diseases which are expected to impair cognitive functions * Any history of speech or language impairment predating the current condition * Patients with alcohol consumption \>21 standard alcohol units per week. Model B: * Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis) * MMSE score \< 16 * Patients unable to give consent * Patients with concomitant psychosis or severe psychiatric comorbidities other than depression * Any history of speech or language impairment predating the current condition

Design outcomes

Primary

MeasureTime frameDescription
Model A: Primary measure is the AUC-ROC of the model in distinguishing between MCI and AD as well as between MCI and cognitively healthy control participants.At baseline (speech recording)We will measure the AUR-ROC of AI predictions compared to clinical consensus diagnosis. Metrics will be presented including uncertainty estimates. Model performance will be measured on an independent test-set consisting of patients from the model B training population.

Secondary

MeasureTime frameDescription
Accuracy for dementia vs. depressionAt baseline (speech recording)Measured by sensitivity, specificity, AUR-ROC of AI predictions compared to clinical consensus diagnosis, using baseline speech recordings from participants. Model performance will be measured after database lock at study completion.
Sub-classification of Mild Cognitive Impairment (MCI) into progressive vs. non-progressiveAt baseline (speech recording) and up to 12 months after enrollment (to determine progression)Measured by sensitivity, specificity, AUR-ROC of AI predictions compared to clinical consensus diagnosis, using baseline speech recordings from participants. Model performance will be measured after database lock at study completion. Progression is defined as new dementia diagnosis during study period.
Classification of dementia subtypes (AD, VaD, LBD, FTD)At baseline (speech recording)Measured by sensitivity, specificity, AUR-ROC of AI predictions compared to clinical consensus diagnosis, using baseline speech recordings from participants. Model performance will be measured after database lock at study completion.
Comparison with established biomarkersAt baseline, or at time of biomarker testing if performed after baselineDifferences in diagnostic accuracy between AI predictions and state-of-the-art biomarkers for dementia diagnosis
Feature importance analysisAt baseline (speech recording)Feature importance will be evaluated using interpretability analyses (e.g. permutation importance, SHAP values, and/or ablation of feature groups) to quantify the contribution of acoustic and linguistic features to the model's predictions.

Countries

Denmark

Contacts

CONTACTSofie J Vængebjerg, MD
sova@regsj.dk+4530294621
CONTACTPeter Høgh, MD, PhD, Assoc Prof
phh@regionsjaelland.dk+45 22526698
PRINCIPAL_INVESTIGATORPeter Høgh, MD, PhD, Assoc Prof

Zealand University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026